Form 4: Solid Biosciences' Chief Medical Officer Reports Stock Transactions

Gabriel Brooks, Chief Medical Officer of Solid Biosciences, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Summary

• On October 18, 2024, Gabriel Brooks, Chief Medical Officer of Solid Biosciences, exercised restricted stock units (RSUs) converting into 9,750 shares of common stock.
• Following the vesting, Mr. Brooks sold 2,923 shares of common stock on October 21, 2024, at a price of $6.5 per share.
• The sale was made to cover withholding taxes associated with the vesting of the RSUs.
• After these transactions, Mr. Brooks directly owns 10,979 shares of Solid Biosciences common stock.
• Mr. Brooks also owns 29,250 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when company insiders, like the Chief Medical Officer, trade in their company's stock. It provides transparency to the market regarding insider activity.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The transactions reported are typical for executives who receive stock-based compensation.
• Similar filings are made by executives at companies like Sarepta Therapeutics and BioMarin Pharmaceutical when they exercise options or sell shares.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company insider.
• The sale of shares to cover withholding taxes is a common practice and generally doesn't significantly affect the company's operations or financial health.

Key Dates